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Background: Primary immunodeﬁciency disorders (PIDs) are an impor-
tant but under-diagnosed cause of childhood morbidity and mortality.
HSCT is the curative treatment for PIDs. Finding a matched donor is a
stumbling block. Moreover, presence of severe infections at the time of
transplants increases the transplant-related mortality (TRM. Poor infra-
structure in developing world adds to the Gordian knot. So, RIC HSCT has
been reported as a safer modality.
Objectives: To describe the feasibility and outcome of RIC HSCT for PIDs.
Methods: Twelve children with various PIDs, from August 2013 to August
2016 who underwent HSCT under our care were included. Clinical records
were analyzed retrospectively.
Results: Twelve children (SCID-2, DOCK-8 deﬁciency-1, Chediak-Higashi
Syndrome-1, WAS-3, HLH-2, GATA2 mutation-1 and CVID-1, HO-1 deﬁ-
ciency-1) with mean age 5.72 year underwent HSCT. Male: Female ratio
was 11:1. Mean follow-up 419 days (9 to 1209 days). Eight underwent
haploidentical HSCT three had matched sibling donor (MSD) HSCT, and
one had MUD HSCT. In seven T-cell replete haploidentical and one MUD
HSCT the conditioning was with serotherapy (Alemtuzumab-4 or Rabbit
Anti-Thymoglobulin-4) along with Fludarabine, Cyclophosphamide, Thio-
tepa and TBI in 5, Fludarabine and Treosulfan in 2 and Fludarabine and
Busulfan in 1. All received post transplant cyclophosphamide 50 mg/kg on
day 3 and 4 for GVHD prophylaxis along with tacrolimus and MMF. In one,
TCR alpha-beta/CD19 depleted haploidentical HSCT the conditioning was
Alemtuzumab, Fludarabine, Treosulfan and Thiotepa with no GVHD pro-
phylaxis. Two MSD were conditioned with Anti-Thymoglobulin, Fludar-
abine and Cyclophosphamide and GVHD prophylaxis was cyclosporine and
methotrexate and one MSD was given Alemtuzumaab, Fludarabine,
Cyclophosphamide and TBI with Tacrolimus and MMF for GVHD prophy-
laxis. Mean CD34+ cell dose was 14.24106/kg for 8 patients with PBSC
graft and 32.1106/kg for 4 patients who got bone marrow. Ten patients
engrafted and two died prior to engraftment with bacterial sepsis on day
+8 and day+14 respectively. Mean neutrophil engraftment was on 16.8 day.
One patient died with thrombotic microangiopathy on day+28. Eight
survivors are fully donor (>95%) and one had mixed chimerism (85%).
Acute GVHD grade I-II developed in 4 children. Chronic GVHD of skin
developed in two. CMV reactivation was seen in two and BCG reactivation
in two. Overall survival 75% and TRM 25%.
Conclusion: RIC HSCT constitutes a feasible option for PIDs in developing
world and gives a ray of hope for these patients.
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Abstract
Background/Objectives: Donor availability remains one of the major
challenges for performing hematopoetic stem cell transplantation (HSCT)
in the treatment of hematologic malignancies. Matched sibling or unre-
lated donor cannot be identiﬁed or mobilized in time for many patients.
HLA-haploidentical donor transplantation (HIDT) using Tcell replete grafts
and post-transplantation cyclophosphamide (PTCY) for control of allor-
eactivity has emerged as an important option for patients who lack a
donor. Post-transplant cyclophosphamide (PTCY) is not toxic to hemato-
poietic stem cells because of high expression of enzyme aldehyde dehy-
drogenase but it induces selective allodepletion by killing host and donor T
cells proliferating in response to donor and host cells, respectively. Thus,
PTCY decreases GvHD but doesnot effect GvL. We report here the feasi-
bility and outcome of HIDT in a developing world setting.
Designs/Methods: Six children with hematological malignancies and no
available matched donor underwent HIDT from Dec2013 to Sept2016. The
clinical records and investigation sheets were analyzed retrospectively.
Patient's follow-up ranged from Day+10 to Day+732 (Mean Day+278)
Results: Mean age was 4.88 year (1.6-9 years). M:F ¼ 3:3. All had hemato-
logical malignancies (High risk Acute myeloid leukemia-2, Relapsed acute
lymphoblastic leukemia-4) and all were in complete remission (CR) at thetime of transplant. Conditioning was Fludarabine (40mg/m2/day) from Day-
8 to day-5, Cyclophosphamide (14.5mg/kg/day) on Day-4 and Day-3, Thio-
tepa (8mg/kg/day) on Day-2 and TBI (2Gy) on Day-1. All patients received
haploidentical peripheral blood stem cells. Mean CD34+ cell dose was 12.7
106/kg/recipient weight. PTCY (50 mg/kg/day) was given on Day+3 and
Day+4. Tacrolimus and MMF were started from Day+5 for Graft-Vs-Host
disease (GvHD) prophylaxis. Supportive care along with Voriconazole and
Valacyclovir for antifungal and antiviral prophylaxis was given. Five patients
engrafted while one awaits engraftment (short follow-up). Mean neutrophil
engraftment was on 18.6 day. Immediate post-transplant period was un-
eventful. Only one patient had viral reactivation, who had Adenovirus
induced hemorrhagic cystitis on Day+44 which was successfully treated
with Cidofovir. Chimerism studies showed fully donor in all patients who
were post Day+100. One patient of Pre-B ALL relapsed on Day+406 of HIDT.
This patient was very difﬁcult to bring in remission even before the trans-
plant and is now being taken up for the next transplant. Acute GVHD was
not seen in any patient. Chronic GVHD of skin was seen in two patients
which was conservatively managed. All six patients are alive.
Conclusion: In hematological malignancies patients who have no
matched donor available, HIDT with PTCY constitutes a feasible and
effective option.
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Background: Haploidentical stem cell transplantation in children with
benign haematological disorders offers a unique opportunity to cure a
child who has no matched family donor. However, the associated chal-
lenges are different to conventional allograft making the options subop-
timal so far. Recent advances have made this procedure feasible in very
young children and we describe our experience in the use of this
technique.
Patients andmethods: The studywas conducted at the blood andmarrow
transplantation unit at Apollo Hospital, Chennai. Children aged up to 18
years who underwent haploidentical transplantation from 2002 to 2016
were included in the study.
Results: A total of 23 paediatric haploidentical stem cell transplantations
have been performed at our centre so far. Of these 16/23 (69.5%) have been
for benign disorders including Fanconi anaemia in 3, Haemophagocytic
LymphoHistiocytosis in 2, 1 with severe aplastic anaemia and 10 with
primary immunedeﬁciency disorders namely, severe combined immune-
deﬁciency in 6, 1 each with Wiskott Aldrich syndrome, Hyper IgM syn-
drome, MSMD and Adrenoleukodystrophy. The sources of stem cells were
from sibling and parent and bone marrow and peripheral blood in equal
numbers. Techniques of T depletion used were CD 34 selection in 1,
Campath in the bag in 1, TCR alpha/beta depletion 2, CD3/19 depletion in 1
and post transplant cyclophosphamide (PTCy) in 11 children.
In transplants where PTCy was used, conditioning included Fludarabine/
Treosulphan in primary immunedeﬁciency, Fludarabine/ Treosulphan/
single dose TBI 200cGy in HLH, Fludarabine/ Cyclophosphamide/ single
dose TBI 200cGy in Fanconi anaemia and severe aplastic anaemia. In the
child with ZAP70 mutation where TCR alpha/beta depletion was used,
conditioning regimen included Fludarabine/ Treosulphan/ Thiotepa/ ATG.
12/16 (75%) transplants resulted in engraftment by Day 16-21 post HSCT
with sustained complete chimerism. Hyper IgM syndrome and MSMD
were 2 conditions where primary rejection resulted in autologous recon-
stitution. Acute skin and gut GVHD of grade 2-3 was noted in 5/16 (31%)
which was responsive to steroids. Chronic skin and mouth GVHD has been
noted in 1 child. CMV reactivation was noted in 5/16 (31%) children
wherein 4 children achieved negative CMV copies on treatment with
Valganciclovir.
Mortality among this group of patients was found to be 6/16 (37.5%). In the
PTCy group, 3 children died of aspergillosis, severe ARDS and ruptured
peliosis hepatis respectively. Campath use resulted in refractory CMV
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lection was used died of progressive leukoencephalopathy probably of
viral etiology.
Conclusions: Haploidentical stem cell transplantation is a feasible option
for cure in children with lifethreatening benign disorders where no
compatible family or matched unrelated donor has been found with
engraftment rates of 75% and overall survival of 55%. Up to 30% can develop
CMV viral reactivation and acute GVHD. PTCY in infants caused lethal
neurological side effects andmortality and should not be recommended. In
our series, we have had superior outcome with the use of PTCy compared
to ex vivoT depletionwith survival rates of 55%. The cost of themonoclonal
antibodies alone is about 12 lakhs making this procedure twice as
expensive compared to PTCY. Careful patient selection will improve out-
comes using this simple but cost effectivemethod of treating childrenwith
benign haematological conditions in the future.
SCT-1_V1.4
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA. A
SINGLE CENTER EXPERIENCE FROM INDIA
Waseem Iqbal, Sonamani Ngangbam, Shobha Badiger, Sharat
Damodar, K.S. Nataraj, B.R. Prathip, Sunil Bhat. Mazumdar Shaw Cancer
Center, Narayana Health City, Bangalore, India
E-mail address: sunilbhat_9@hotmail.com (S. Bhat).
Introduction: Thalassemias are the most common inherited single gene
disorders of the hemoglobin production prevalent all across the world
especially in the Thalassemia belt extending eastward from the Mediter-
ranean to South East Asia. Although conservative management with reg-
ular blood transfusions and effective chelation have improved the short
term outlook, allogeneic bone marrow transplantation provides the only
option of complete cure.
Methods: We retrospectively analyzed the outcomes of patients diag-
nosed with Thalassemia who underwent allogeneic hematopoietic
stem cell transplantation at our institute from November 2004 to July
2016.
Results: One hundred Thalassemia patients [Males n¼56 (56 %); Females
n¼44 (44%)] with a median age of 7 years (range 2 to 24 years) under-
went HSCT during this period. Seventy six (76%) were classiﬁed as Pesaro
Class 2 and 18 (18%) as Class 3. Six (6%) patients were classiﬁed as Pesaro
Class 1. The donor type was Matched sibling in 84 (84%), Matched Related
in 2 (2%), Matched Unrelated in 9 (9 %) and Haploidentical in 5 (5 %)
patients. Stem cell source was Marrow, Peripheral stem cells and Cord in
67 (67%), 29 (29%) and 1 (1%) patients respectively. Two patients (2%)
received both marrow as well as peripheral stem cells, whereas 2 (1%
each) received cord blood and cord plus marrow respectively. Of the 29
PBSCTs done, 4 were from a matched unrelated donor (MUD) and 5 (5%)
were from haploidentical donors. The conditioning regimens used con-
sisted of Flu-Bu-Cy-ATG (n¼45) [45%], BU-CY-ATG (n¼25) [25%], FLU-
THIO-TREO-ATG (n¼16)[16%], FLU-THIO-TREO (n¼8) [8%], FLU-BU-CY-
THIO-ATG (n¼2) [2%], BU-CY (n¼2) [2%] and FLU-BU-CY-RITUXIMAB,
FLU-BU-CY-TBI AND each [0.9% each). Majority of the recipients received
Cyclosporine and Methotrexate as GVHD prophylaxis (n¼88; 88%). The
median MNC and CD34 cell dose for patients who had received marrow
and/or peripheral stem cells was 7.4108/kg (range 2.1 to 23 108/kg)
and 4.5106/kg (range 0.66 to 38 106/kg) respectively. The patient who
underwent cord blood transplant received a MNC dose of 0.51X 108/kg
and a CD34 dose of 0.4X106/kg. Hematological recovery was seen in all
patients except two (2) patients that also included the cord blood
transplant recipient, who died before engraftment. Neutrophil and
platelet engraftment occurred at a median of 14 days (range, 8-24 days)
and 21 days (range, 8-72 days), respectively. Thirty seven (37%) patients
developed veno-occlusive disease. Thirty three patients (33%) developed
Grade I-IV GVHD, 22 (23.3%) had Grade II-IV GVHD and 4 (4%) had Grade
III-IV GVHD. Six (6%) patients had chronic GVHD. At day +28, sixty (60%)
patients showed more than 90% donor chimersim and 34 (34%) had
mixed chimerism. Five (5%) patients had expired before day +28 before
chimerism could be done. One patient had primary rejection. Six patients
(6%) patients experienced secondary graft rejection. Amongst patients
who were more than day 100 at the time of analysis, the Treatment-related mortality (TRM) for the whole cohort was 12%. TRM was 8.3% and
33.34% for Class 2 and class 3 patients respectively. At a median follow up
of 25 months, overall survival and thalassemia free survival were 85.3%
and 77.3% respectively.
Conclusion: Similar outcomes have been reported from developed
countries. Outcome of Class 3 patients still continues to be poor and VOD
rates are high in this patient group.
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Background: Allogenic Hematopoietic Stem Cell Transplantation (HSCT)
has been an established curative option for a number of non-malignant
and malignant disorders. Unfortunately, most children in our country are
unable to avail of this option due to non-affordability and its non-avail-
ability in public sector hospitals. We share our experience of establishing a
Hematopoietic Stem Cell Transplant Unit at Lokmanya Tilak Municipal
General Hospital, a civic hospital in Mumbai. Till date, over one year, we
have performed eight hematopoietic stem cell transplants for various
indications.
Objective: To share the experience and challenges in establishing a HSCT
unit in a Public Hospital.
Method: The need for a Hematopoietic Stem Cell Transplant (HSCT) centre
was always felt with indications for HSCT being identiﬁed in increasing
number of children. The idea of setting up a HSCTcentre, though conceived
in 1998, could not materialize till 2012, as there was no source for funding
available. After the major hurdle of funds was taken care of by a philan-
thropic organization, the task of administrative approval, space allocation
and getting the desired infrastructure in place began in 2013. Funds were
utilized for building the state-of-the-art 20-bedded Pediatric Hematology-
Oncology Unit with one bedded HSCT centre. The purchase of equipment
and staff recruitment was done simultaneously. Training of the selected
staff, including the paramedical personnel and team building was initiated.
The process of team building was taken up before the unit became func-
tional and experts with experience in HSCT were invited to join the
existing team of doctors in the Pediatric Hematology-Oncology Division.
Donor funding was ensured for pre-HSCT workup, process of trans-
plantation and post-transplant care. Patients in whom HSCT was consid-
ered curative and who had a matched sibling donor were considered for
transplant.
Results: The HSCT unit was operational by August 2015 and 8 patients
have been transplanted till date. These include 4 children with Severe
Aplastic Anemia (SAA), 3 with Thalassemia Major (TM) and 1 infant with
Severe Combined Immune Deﬁciency- Reticular Dysgenesis (SCID). HSCT
with matched sibling donor was done in 7 patients, whereas, father was
the donor for the infant with SCID with a 9/10 match. Reduced Intensity
Conditioning (RIC) consisting of Flu-Cy-ATG was used in patients with SAA
and Treo-Thio-Flu-ATG was administered to the baby with SCID. For 2 of 3
TM belonging to class II by Pesaro classiﬁcation, myeloablative regimen
consisting of Bu-Cy-ATG was used, whereas the third thalassemic, who
was Class III, a reduced intensity regimen with Treo-Thio-Flu-ATG was
given. Peripheral blood stem cells (PBSC) was the source of stem cells in
SAA and SCID, whereas bone marrow harvest was done for TM. Challenges
faced included blood group mismatch in 6 of these patients - major ABO
mismatch in 3, minor ABOmismatch in 2 of them and 1 with Rhmismatch.
Seven of the 8 patients are free of their disease, with no GVHD or any other
complications at a follow up ranging from 20 days to 1 year 8 days. The
infant with SCID died of adenoviral infection during immediate post-
transplant period during the severely neutropenic phase.
Conclusion: It is feasible to set up a HSCT unit in a public sector hospital if
one has the vision, passion and commitment. Presently, there are hardly
